Cargando…
siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model
Pancreatic cancer is characterized by late detection, frequent drug resistance, and a highly metastatic nature, leading to poor prognosis. Antibody-based immunotherapy showed limited success for pancreatic cancer, partly owing to the low delivery rate of the drug into the tumor. Herein, we describe...
Autores principales: | Jung, Jae Yun, Ryu, Hyun Jin, Lee, Seung-Hwan, Kim, Dong-Young, Kim, Myung Ji, Lee, Eun Ji, Ryu, Yeon-Mi, Kim, Sang-Yeob, Kim, Kyu-Pyo, Choi, Eun Young, Ahn, Hyung Jun, Chang, Suhwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534711/ https://www.ncbi.nlm.nih.gov/pubmed/34685714 http://dx.doi.org/10.3390/cells10102734 |
Ejemplares similares
-
Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis
por: Choi, Yeon-Sook, et al.
Publicado: (2022) -
Inhibition of Tumor Growth via Systemic siRNA Delivery Using Reducible Bile Acid-Conjugated Polyethylenimine
por: Yin, Yue, et al.
Publicado: (2018) -
Galactosylated Liposomes for Targeted Co-Delivery of Doxorubicin/Vimentin siRNA to Hepatocellular Carcinoma
por: Oh, Hea Ry, et al.
Publicado: (2016) -
Improved efficacy and in vivo cellular properties of human embryonic stem cell derivative in a preclinical model of bladder pain syndrome
por: Kim, Aram, et al.
Publicado: (2017) -
AsiDesigner: exon-based siRNA design server considering alternative splicing
por: Park, Young-Kyu, et al.
Publicado: (2008)